Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Cureus ; 16(2): e54939, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38544619

RESUMEN

This case report underscores the effective implementation of a delivery plan for a pregnant patient, focusing on a successful case study where a cesarean section, preceded by the pre-treatment of intravenous plasma-derived C1 inhibitor, resulted in the delivery of a healthy baby. The proposed delivery plan offers a systematic approach to managing hereditary angioedema during pregnancy. It recommends opting for delivery at an academic center equipped with high-risk obstetric care, obstetric anesthesia, and a level 4 Neonatal Intensive Care Unit. The plan also emphasizes the importance of early admission at the onset of labor and delineates specific protocols for both vaginal and cesarean deliveries.

2.
J Clin Immunol ; 42(8): 1600-1603, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-35821452

RESUMEN

A 10-month-old boy was diagnosed with X-linked lymphoproliferative syndrome type 2 due to X-linked inhibitor of apoptosis deficiency after presenting with failure to thrive and refractory inflammatory bowel disease. He underwent a matched unrelated donor stem cell transplant with reduced intensity conditioning at 16 months. At 27 months, he presented with an atypical inflammatory syndrome in the setting of recent COVID-19 infection, Epstein-Barr viremia, and low chimerism (7.3%). He recovered after treatment with intravenous immunoglobulin and steroids.


Asunto(s)
COVID-19 , Trasplante de Células Madre Hematopoyéticas , Trastornos Linfoproliferativos , Masculino , Humanos , Preescolar , Lactante , Proteína Inhibidora de la Apoptosis Ligada a X , SARS-CoV-2 , COVID-19/diagnóstico , Trastornos Linfoproliferativos/diagnóstico , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Apoptosis
4.
J Clin Immunol ; 41(7): 1457-1462, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34089457

RESUMEN

While adults with Down syndrome (DS) are at increased risk of severe COVID-19 pneumonia, little is known about COVID-19 in children with DS. In children without DS, SARS-CoV-2 can rarely cause severe COVID-19 pneumonia, or an even rarer and more typically pediatric condition, multisystem inflammatory syndrome in children (MIS-C). Although the underlying mechanisms are still unknown, MIS-C is thought to be primarily immune-mediated. Here, we describe an atypical, severe form of MIS-C in two infant girls with DS who were hospitalized for over 4 months. Immunological evaluation revealed pronounced neutrophilia, B cell depletion, increased circulating IL-6 and IL-8, and elevated markers of immune activation ICAM1 and FcÉ£RI. Importantly, uninfected children with DS presented with similar but less stark immune features at steady state, possibly explaining risk of further uncontrolled inflammation following SARS-CoV-2 infection. Overall, a severe, atypical form of MIS-C may occur in children with DS.


Asunto(s)
COVID-19/diagnóstico , Síndrome de Down/diagnóstico , SARS-CoV-2/fisiología , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico , COVID-19/complicaciones , Síndrome de Down/complicaciones , Resultado Fatal , Femenino , Hospitalización , Humanos , Lactante , Síndrome
10.
J Clin Immunol ; 40(3): 456-465, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31997108

RESUMEN

In 2010, the New York State (NYS) Newborn Screen (NBS) Program added the T cell receptor excision circle (TREC) assay to screen for severe combined immunodeficiency disorder (SCID). The objective of this study was to perform a retrospective chart review of 199 infants referred to a single institution for abnormal TREC on NYS NBS between 2010 and 2017. Statistical analysis included analysis of variance, logistic regression models, chi-square, and linear mixed models. One hundred ninety-nine infants were found to have a TREC value of fewer than 200 copies/µL on NYS NBS. Infants were stratified as primary immunodeficiency (PID) (n = 54), immunocompetent (n = 133), lost to follow-up (n = 8), or deceased (n = 4). PID included SCID (n = 3), DiGeorge (n = 6), idiopathic lymphopenia (IL) (n = 44), and other syndromes associated with lymphopenia (n = 3). The 3 SCID cases were identified and brought to treatment, although all experienced significant infections. The study population was found to be predominately non-Hispanic, African American, and male. There was a difference in the average TREC values among those with immunocompetence (83 copies/µL), IL (81 copies/µL), and PID (40 copies/µL) (p < 0.05). On follow-up of 40 patients with IL, patients typically did not have severe infections during first few years of life. This study demonstrates that TREC value can be used to stratify infants for further confirmatory testing to exclude PID. Risk factors, such as stressful prenatal/postnatal conditions, prematurity, race, and sex may affect TREC value but cannot explain all causes of lymphopenia. This study may assist providers in risk stratifying the likelihood of PID with an abnormal TREC and determining the extent of the initial work up that is necessary at the time of a newborn's presentation.


Asunto(s)
Negro o Afroamericano , Tamizaje Neonatal/métodos , Receptores de Antígenos de Linfocitos T/genética , Inmunodeficiencia Combinada Grave/diagnóstico , Femenino , Estudios de Seguimiento , Humanos , Lactante , Recién Nacido , Linfopenia , Masculino , New York/epidemiología , Estudios Retrospectivos , Factores de Riesgo , Centros de Atención Secundaria , Inmunodeficiencia Combinada Grave/epidemiología
13.
Paediatr Respir Rev ; 36: 118-127, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31678040

RESUMEN

Asthma is a common disease in paediatrics and adults with a significant morbidity, mortality, and financial burden worldwide. Asthma is now recognized as a heterogeneous disease and emerging clinical and laboratory research has elucidated understanding of asthma's underlying immunology. The future of asthma is classifying asthma by endotype through connecting discernible characteristics with immunological mechanisms. This comprehensive review of the immunology of asthma details the currently known pathophysiology and clinical practice biomarkers in addition to forefront biologic and targeted therapies for all of the asthma endotypes. By understanding the immunology of asthma, practitioners will be able to diagnose patients by asthma endotype and provide personalized, biomarker-driven treatments to effectively control patients' asthma.


Asunto(s)
Asma/inmunología , Citocinas/inmunología , Leucotrienos/inmunología , Células TH1/inmunología , Células Th2/inmunología , Asma/clasificación , Asma/fisiopatología , Asma/terapia , Asma Inducida por Aspirina/inmunología , Asma Inducida por Aspirina/fisiopatología , Asma Inducida por Aspirina/terapia , Asma Inducida por Ejercicio/inmunología , Asma Inducida por Ejercicio/fisiopatología , Asma Inducida por Ejercicio/terapia , Productos Biológicos , Biomarcadores , Eosinofilia/inmunología , Eosinofilia/fisiopatología , Eosinofilia/terapia , Humanos , Aspergilosis Pulmonar Invasiva/inmunología , Aspergilosis Pulmonar Invasiva/fisiopatología , Aspergilosis Pulmonar Invasiva/terapia , Terapia Molecular Dirigida , Obesidad/inmunología , Obesidad/fisiopatología , Estrés Oxidativo/inmunología , Fenotipo , Hipersensibilidad Respiratoria/inmunología , Hipersensibilidad Respiratoria/fisiopatología , Hipersensibilidad Respiratoria/terapia , Ruidos Respiratorios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA